Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey
      • Physician Segmentation
      • Outcomes
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
      • Risk Adjustment & Quality Analytics
  • Company
    • Careers
    • Events
    • News
    • Insights
  • Contact Us
Home Insights What to Consider if Your Drug is a Targeted Therapy for a New Biomarker

What to Consider if Your Drug is a Targeted Therapy for a New Biomarker

  • April 4, 2019
  • Posted in Lab Testing Insights

This post was last updated on December 29, 2020 at 1:41 pm

Biomarker vials

A Follow Up to “Biomarker Testing in Non-Small Cell Lung Cancer“

By Melissa Leonhauser, General Manager, Alert & Targeting Portfolio

More and more targeted cancer therapies are being developed. But, after approval, the brand team faces an uphill battle in getting physicians to test for any new biomarkers the drugs are intended to treat. As my colleague Bill explained in his blog on NSCLC testing, physicians are much less likely to test for biomarkers that are new or don’t have one or two approved targeted therapies.

Bill analyzed testing of non-small cell lung cancer patients and found that PD-L1 is the most widely tested for mutation with EGFR mutation and ALK gene rearrangement testing following.  Each of these biomarkers has had targeted therapies approved and on the market for years. Newer biomarkers such as ROS1, are tested for at a lower rate. In 2018, 85% of NSCLC patients were tested for PD-L1 expression but only 49% were tested for ROS1 gene rearrangement.

With this knowledge, brand teams for drugs targeted at new or newer biomarkers should prepare a strategy to positively influence physicians to increase testing for that biomarker.  Afterall, physicians aren’t likely to treat with the drug if it isn’t discovered that the patient has the gene mutation or expression the drug targets. More tests = more eligible patients found.

The brand team should set a reasonable expectation for how much testing is likely to occur in the first year or first 6 months after launch by looking at the uptake of testing for other biomarkers, similar to how they may have used a drug analog to forecast launch performance.  For instance, if the drug launching treats non-small cell lung cancer, they could look at trends in ROS1 testing and the launch of Xalkori.

In addition, brand teams can look at which physicians were early adopters of other new biomarker tests.  It’s likely that these physicians would be the first to test for their targeted biomarker as well. A physician who typically treats patients with the malignancy AND is an early adopter of new testing, should surely be educated on their treatment early on and often.

« Available Omnichannel HCP Data Sources
Deterministic or predictive profiles? How to optimize your HCP promotional activities across channels »

Categories

  • AI
  • Alerts
  • Clinical
  • Commercial Launch Excellence
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Omnichannel Marketing
  • Physician Segmentation
  • Prog Spotlight
  • Technology

Archives

Latest Tweets

Prognos HealthFollow

Prognos Health
prognosAIPrognos Health@prognosAI·
19 Feb

#HealthcareAnalytics are evolving.

On Tuesday February 23, Prognos Health co-founder and CEO, @sundeepbhan, will join @Safeguard for a virtual discussion on the healthcare data revolution with @GKurtzman.

Register: https://us02web.zoom.us/webinar/register/WN_WlCiq5v2TICwSMRi-PVGZw

#HealthcareData #prognosFACTOR

Reply on Twitter 1362875761674354689Retweet on Twitter 1362875761674354689Like on Twitter 1362875761674354689Twitter 1362875761674354689
prognosAIPrognos Health@prognosAI·
11 Feb

Find a way, or make a way. It’s the Prognos mantra embraced by Ali Koc, VP of Engineering at Prognos Health.

In his latest blog post, Ali writes about making data accessible at web speeds, and how it enables data analysis in a truly new way.

https://prognoshealth.com/blog/find-a-way-or-make-a-way-building-an-interactive-analytics-platform-that-speaks-healthcare/

#HealthTech

Reply on Twitter 1359933724088020994Retweet on Twitter 1359933724088020994Like on Twitter 13599337240880209942Twitter 1359933724088020994
prognosAIPrognos Health@prognosAI·
28 Jan

#TBT to our webinar featuring #LifeSciences thought leaders from @Novartis, @TakedaPharma, and @pfizer as well as Prognos Co-founder @jmbhan.

Our latest blog explores 9 insights from these experts for driving #Commercial #LaunchExcellence in #Pharma

https://prognoshealth.com/blog/overheard-at-the-reuters-health-webinar-9-insights-for-driving-commercial-launch-excellence/

Reply on Twitter 1354901342679146499Retweet on Twitter 1354901342679146499Like on Twitter 13549013426791464991Twitter 1354901342679146499
prognosAIPrognos Health@prognosAI·
22 Jan

Uncovering the (Clinical) Truth.

Bill Bowman and @olatulekan write about the intersection where #MachineLearning meets disease-specific #clinical knowledge - #ClinicalTruths - and how this improves #PatientOutcomes with #HealthcareAnalytics at scale.

https://prognoshealth.com/blog/uncovering-the-clinical-truth/

Reply on Twitter 1352709796135391237Retweet on Twitter 13527097961353912371Like on Twitter 13527097961353912373Twitter 1352709796135391237
prognosAIPrognos Health@prognosAI·
31 Dec

As we ring in the new year, there's so much to look forward to. We wish all of our clients, and partners a healthy, happy new year and are excited to continue innovating together in 2021 to positively impact care.

Reply on Twitter 1344647644669468672Retweet on Twitter 1344647644669468672Like on Twitter 13446476446694686722Twitter 1344647644669468672
Load More...
  • prognosFACTOR®
    • Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • Events
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2021. All Rights Reserved.

See What Decision Speed Looks Like in Action

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.